<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
    <channel>
        <title><![CDATA[Aaron S Kesselheim - Dir:PORTAL/Professor:Medicine]]></title>
        <description><![CDATA[Aaron S. Kesselheim is an associate professor of medicine at Harvard Medical School and the director of the Program on Regulation, Therapeutics and Law at Brigham and Women’s Hospital.
]]></description>
        <link>https://www.bloomberg.com/authors/ATSW7LWzNlY/aaron-s-kesselheim</link>
        <generator>RSS for Node</generator>
        <lastBuildDate>Sun, 10 May 2026 14:36:33 GMT</lastBuildDate>
        <atom:link href="https://www.bloomberg.com/authors/ATSW7LWzNlY/aaron-s-kesselheim.rss" rel="self" type="application/rss+xml"/>
        <copyright><![CDATA[Copyright 2026 BLOOMBERG L.P. ALL RIGHTS RESERVED]]></copyright>
        <language><![CDATA[en]]></language>
        <item>
            <title><![CDATA[To Ensure Access to Covid Vaccines, Demand a Fair Price]]></title>
            <description><![CDATA[After the federal government is no longer buying all the doses, it will need to see that patients and insurers aren’t overcharged.]]></description>
            <link>https://www.bloomberg.com/opinion/articles/2021-01-22/to-ensure-access-to-covid-vaccines-demand-a-fair-price</link>
            <guid isPermaLink="true">https://www.bloomberg.com/opinion/articles/2021-01-22/to-ensure-access-to-covid-vaccines-demand-a-fair-price</guid>
            <category><![CDATA[world]]></category>
            <dc:creator><![CDATA[Aaron S Kesselheim]]></dc:creator>
            <pubDate>Fri, 22 Jan 2021 13:30:53 GMT</pubDate>
            <media:content url="https://assets.bwbx.io/images/users/iqjWHBFdfxIU/indw_OnBRjsM/v1/piHJkQ_WoLj1E/-1x-1.jpg" type="image/jpeg">
                <media:thumbnail url="https://assets.bwbx.io/images/users/iqjWHBFdfxIU/indw_OnBRjsM/v1/piHJkQ_WoLj1E/-1x-1.jpg"/>
                <media:description>A small bottle that needs a small pricetag.</media:description>
            </media:content>
        </item>
        <item>
            <title><![CDATA[Get Generic Drugs to Market Faster]]></title>
            <description><![CDATA[One good way Congress can bring down the cost of prescription medicines.]]></description>
            <link>https://www.bloomberg.com/view/articles/2017-06-20/get-generic-drugs-to-market-faster</link>
            <guid isPermaLink="true">https://www.bloomberg.com/view/articles/2017-06-20/get-generic-drugs-to-market-faster</guid>
            <category><![CDATA[view]]></category>
            <dc:creator><![CDATA[Ameet Sarpatwari]]></dc:creator>
            <pubDate>Tue, 20 Jun 2017 11:00:15 GMT</pubDate>
            <media:content url="https://assets.bwbx.io/images/users/iqjWHBFdfxIU/izTlJtxaDOus/v0/piHJkQ_WoLj1E/-1x-1.jpg" type="image/jpeg">
                <media:thumbnail url="https://assets.bwbx.io/images/users/iqjWHBFdfxIU/izTlJtxaDOus/v0/piHJkQ_WoLj1E/-1x-1.jpg"/>
                <media:description>Ranbaxy Laboratories Ltd.&apos;s Atorvastatin Calcium Tablets IP Storvas 10 tablets are arranged for a photograph in Mumbai, India, on Thursday, Feb. 20, 2014. The U.S. is increasing scrutiny of generic drugs made in India, and in the past nine months banned imports from four plants belonging to Ranbaxy Laboratories Ltd. and Wockhardt Ltd. Photographer: Dhiraj Singh/Bloomberg via Getty Images</media:description>
            </media:content>
        </item>
    </channel>
</rss>